Aminophenazone

Producers shown on SFDA

(Record date:18/10/2021）

Producers shown on EP

Not showing any

Producer:Zhejiang Haisen Pharmaceutical Co., Ltd., located in Liushi street, Dongyang City, is a national high-tech enterprise engaged in the R & D, production and operation of APIs and pharmaceutical intermediates. The company covers an area of 70000 square meters and has more than 400 employees, including professional technicians   More than 30%.

The company passed ISO9001:2000 international quality system certification in 2001. It passed the domestic GMP certification for the first time in 2006, obtained the EU CEP Certificate in the same year, and passed the on-site audit of FDA for the first time in 2014. At present, many varieties have been registered in the United States, the European Union, Japan, South Korea, India, Brazil, Mexico and other countries. Among them, sucralfate products account for more than 60% of the world market.

Staff size:400-499 persons

Registered capital:RMB 51 million

Producer:Hebei Jiheng (Group) Pharmaceutical Co., Ltd., established in 1996, is a wholly-owned subsidiary of Hebei Jiheng group.

The company strictly implements GMP standards. Its leading products paracetamol, analgin and folic acid have obtained national GMP certificate, kosher certificate, Indian registration certificate and American DMF registration number. Now they are being certified by American FDA. The pillar product paracetamol has obtained the EU cos certificate; Folic acid has obtained halal certificate. The company has the right to import and export products. Its products are sold to 30 provinces, cities and autonomous regions in China and more than 40 countries and regions such as the Middle East, Southeast Asia, South America, Eastern Europe and Africa, and enjoy a good reputation at home and abroad.

Staff size:900-999 persons

Registered capital:RMB 90 million

Producer:Wuhan Wuyao Pharmaceutical Co., Ltd. is a holding subsidiary invested by Broad (China) Co., Ltd. (formerly Wuhan Pharmaceutical Factory) in 2002. It is a well-known enterprise in the production and operation of specialty drug substances in China. The company passed the acceptance of "secondary enterprise of safety production standardization"; in the same year, it was rated as "high-tech enterprise" in Hubei Province; the annual sales income is 600 million yuan, and the products are exported to more than 40 countries and regions such as Europe and the United States, and the total annual export value $ 50 million.

According to the Opinions of the People's Government of Wuhan City on Accelerating the Relocation and Remediation of Chemical Production Enterprises in the Third Ring Road of the City (Wuzheng [2008] No. 50) and the overall plan, Wuhan Wuyao Pharmaceutical Co., Ltd. was relocated to Yangxin County, Huangshi City, Hubei Province. Chemical Industrial Park of Fuchi Town. The company currently has 820 employees and 500 technical and management personnel with college education or above. With a registered capital of 61 million yuan, the company is a high-tech enterprise engaged in the production and operation of bulk drugs.

Staff size:800-899 persons

Registered capital:RMB 61 million 

Producer:Shandong Xinhua Pharmaceutical Co., Ltd., established in Jiaodong Anti Japanese base in 1943, is the first chemical synthetic pharmaceutical enterprise in China, an important global production and export base of antipyretic and analgesic drugs, and an important domestic manufacturer of cardio cerebrovascular, anti infection and central nervous system. It has three pillar industries of chemical raw materials, pharmaceutical preparations and pharmaceutical intermediates, five industrial parks and 13 subsidiaries. The annual production capacity of chemical APIs is 40000 tons, pharmaceutical intermediates is 500000 tons, solid preparations are 28 billion tablets (tablets), and injections are 1 billion.

At present, all the drugs in production of Xinhua Pharmaceutical have passed the new national GMP certification, 18 products have passed the FDA inspection, 10 products have obtained the EU cos certificate, and the tablets have passed the MHRA audit of the UK drug and health products administration. More than 3 billion tablets have been exported to the EU high-end market, It has become one of the first 15 leading enterprises implementing the internationalization strategy of preparations in China and one of the top ten enterprises in the export of preparations in China.

Staff size:About 7000 persons

Registered capital:RMB 627 million 400 thousand

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978